Circulating tumor DNA, or ctDNA, can predict metastatic risk in patients who receive bladder-sparing treatment for ...

Researchers at the Icahn School of Medicine at Mount Sinai have reported promising findings that may help redefine treatment for patients with muscle-invasive bladder cancer, a potentially aggressive ...

Signatera detects molecular residual disease in bladder cancer by identifying tumor DNA fragments in the bloodstream, even when not visible on scans. The IMvigor010 trial showed that Signatera-guided ...

Although bladder cancer ranks as the sixth most common cancer in the United States, with approximately 85,000 new cases diagnosed each year, it continues to receive limited awareness, advocacy, and ...

Randomized study aims to reduce treatment burden for patients and utilizes Signatera to monitor for disease recurrence AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NTRA) (NASDAQ: NTRA), a global ...

A non-invasive, high-accuracy surveillance test for bladder cancer has the potential to improve patient experience, streamline workflows, and reduce overall cost of care” — Megann Vaughn Watters, Vice ...

Bladder cancer frequently announces itself through symptoms that patients dismiss as minor urinary issues, and that delay ...

New research indicates that about one-quarter of patients with bladder cancer treated with radical surgery on curative intent have detectable levels of tumour cells circulating in their blood. The ...

Bladder cancer signs and symptoms can vary from person to person. The most common symptom is blood in the urine, also called hematuria. While this can turn the urine into a red or rusty color, it may ...

For many people, spotting blood in the urine is often the first warning sign of bladder cancer. But for those with color vision deficiency, commonly called colorblindness, that signal can easily go ...